Find registry-listed psilocybin studies currently marked Recruiting, compare their conditions, phases, sponsors, and study locations, and confirm participation details in the authoritative registry record.
Registry status is not a guarantee of local availability or eligibility. Always verify the study record and contact the listed study team through ClinicalTrials.gov.
Counts below are recomputed automatically from records whose exact ClinicalTrials.gov overall status is RECRUITING.
Leading countries
United States66 trials
Canada15 trials
Israel4 trials
Switzerland3 trials
France2 trials
Sweden2 trials
Brazil2 trials
Denmark2 trials
Common conditions
Depression10
PTSD6
Healthy6
Major Depressive Disorder6
Opioid Use Disorder6
Depression - Major Depressive Disorder5
Anxiety5
Treatment Resistant Depression5
Trial phases
Phase 257
Phase 135
Early Phase 111
Phase 37
Not applicable1
Interactive recruiting map
Explore recruiting study locations
The embedded map opens with the exact Recruiting filter applied. Use its country, condition, phase, intervention, and date controls to refine the current registry view.
How to find and investigate a psilocybin clinical trial
Find a relevant record. Compare the condition, country, phase and sites. This collection uses exact overall Recruiting status; individual sites can have a different status.
Open the ClinicalTrials.gov entry. Read its current participation criteria, last update and contacts. Eligibility is determined by the study team, not by this tracker.
Contact the listed team. Ask whether your local site is accepting inquiries and how its screening works. Neither this website nor ClinicalTrials.gov enrolls participants.
Discuss the study with your clinician. Ask about experimental interventions, alternatives, medication requirements, follow-up and how your usual care would be affected.
Ask about assignment to placebo or other comparison groups, required visits and travel, known risks, support after the intervention, privacy, and how to withdraw. Request a clear explanation of the consent documents. The HHS research-participation question guide provides a fuller checklist.
Do I need to stop antidepressants or other medication?
Requirements vary by protocol and personal circumstances. Read the source criteria and ask the study team and your prescriber. Do not stop or taper medication based on a search result or this list. Missing medication information here does not mean that continuation is allowed.
Are studies free, and do they pay participants?
Costs, compensation and travel support are study-specific. Ask which procedures are covered, what expenses you would bear, whether compensation is offered, and who pays for care if research causes harm. This tracker does not infer financial terms from a Recruiting status.
Does Recruiting mean a place is available near me?
No. Overall registry status does not guarantee availability at a particular site or eligibility for a particular person. A mapped location is a registry-listed site, not a confirmed appointment.
Can participation tell me whether psilocybin will help?
A trial is research with uncertain outcomes. Participants may receive a comparator intervention, and personal benefit is not guaranteed. For published depression findings, read the depression research evidence guide; registrations and outcome reports serve different purposes.
These factual summaries are available without JavaScript. Open the linked ClinicalTrials.gov record for current eligibility, contacts, and site-level availability.
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced Cancer
NYU Langone Health
Conditions
Advanced Cancer
Phase
Phase 2 · Phase 3
Enrollment
200 estimated
Locations
University of Colorado Anschutz Medical campus (CU AMC), Aurora, Colorado, United States · NYU Langone Health, New York, New York, United States
A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
COMPASS Pathways
Conditions
PTSD - Post Traumatic Stress Disorder · PTSD · PTSD Symptoms · PTSD, Post Traumatic Stress Disorder
Phase
Phase 2 · Phase 3
Enrollment
300 estimated
Locations
FL, Miami, Florida, United States · FL, Orlando, Florida, United States · IL, Chicago, Illinois, United States · +5 more
PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin Pretreatment
Johns Hopkins University
Conditions
Mood (Psychological Function) · Well Being · Mood · Healthy
Phase
Phase 1 · Phase 2
Enrollment
20 estimated
Locations
Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States
A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older Adults
University of Colorado, Denver
Conditions
Healthy Volunteer · Older Adults (65-85 Years)
Phase
Phase 1
Enrollment
40 estimated
Locations
University of California San Francisco (UCSF) Department of Neurology, San Francisco, California, United States · University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States · Emory University Brain Health Center, Atlanta, Georgia, United States · +3 more
Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder: A Randomized Controlled Trial
Lakshmi N Yatham
Conditions
Bipolar II Depression
Phase
Phase 2
Enrollment
90 estimated
Locations
Djavad Mowafaghian Centre for Brain Health, Vancouver, British Columbia, Canada · Department of Psychiatry, University of Ottawa, The Ottawa Hospital, Ottawa, Ontario, Canada · Department of Psychiatry, University of Toronto, University Health Network,, Toronto, Ontario, Canada
A Randomized Double-blinded Controlled Trial for the Treatment of Persisting Symptoms After Concussion With Psilocybin-assisted Therapy: A Safety and Feasibility Trial
A Double Blind, Randomized Trial Investigating the Safety, Feasibility, and Mechanisms of Psychedelics in Healthy Older Adults With Low Well-being as Moderated by Biomarkers for Preclinical Alzheimer's Disease
Jennifer Mitchell
Conditions
Anhedonia in Healthy Volunteers · Older Adults (50-90 Years)
Phase
Phase 1
Enrollment
80 estimated
Locations
University of California San Francisco, Sandler Neuroscience Building, San Francisco, California, United States
Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's Disease
Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence in Patients Diagnosed With Early-stage Breast Cancer and Ovarian Cancer in Remission
University of Colorado, Denver
Conditions
Breast Cancer · Ovarian Cancer
Phase
Phase 1
Enrollment
20 estimated
Locations
Outpatient CTRC, Aurora, Colorado, United States · University of Colorado Cancer Center, Aurora, Colorado, United States
The Role of the Subjective Experience in Supporting Positive Effects Following Psilocybin: a Randomized, Controlled Clinical Trial Using Risperidone in Healthy Adults
University of Calgary
Conditions
Investigating the Importance of the Subjective Psychedelic Experience
Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)]
University of California, San Diego
Conditions
Burnout · Burnout, Healthcare Workers
Phase
Phase 1 · Phase 2
Enrollment
30 estimated
Locations
UC San Diego, San Diego, California, United States
A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in Veterans
VA Office of Research and Development
Conditions
Major Depression
Phase
Phase 3
Enrollment
240 estimated
Locations
Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama, United States · Tuscaloosa VA Medical Center, Tuscaloosa, AL, Tuscaloosa, Alabama, United States · VA Portland Health Care System, Portland, OR, Portland, Oregon, United States · +2 more
A Phase 2a, Placebo-Controlled Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder
Claudio N Soares
Conditions
Generalized Anxiety Disorder (GAD)
Phase
Phase 2
Enrollment
50 estimated
Locations
Kingston General Health Research Institute, Kingston, Ontario, Canada
A Randomized Double-masked Dose-controlled Trial to Assess the Tolerability, Safety, Subjective Experience, and Efficacy of Repeated Administration of Three Different Doses of Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.
Francisco A Moreno
Conditions
Obsessive-Compulsive Disorder
Phase
Phase 1
Enrollment
30 estimated
Locations
The Clinical and Translational Sciences Research Center, Tucson, Arizona, United States
A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety
Ohio State University
Conditions
Depression · Anxiety · Major Depressive Disorder
Phase
Phase 2
Enrollment
40 estimated
Locations
The Ohio State University Department of Psychiatry, Columbus, Ohio, United States
Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Trauma-Related Major Depressive Disorder: Randomized Controlled Trial
Khyber Medical University Peshawar
Conditions
Major Depressive Disorder · Post-Traumatic Stress Disorder (PTSD)
Phase
Phase 3
Enrollment
60 estimated
Locations
Institute of Health Science, Khyber Medical University, Islamabad, Capital, Pakistan · Hayatabad Medical Complex Peshawar, Peshawar, KPK, Pakistan · Khyber Medical University, Peshawar, KPK, Pakistan
PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical Trial
Bruyère Health Research Institute.
Conditions
Psychological Distress
Phase
Phase 3
Enrollment
120 estimated
Locations
William Osler Health System, Brampton, Ontario, Canada · Providence Care Hospital, Kingston, Ontario, Canada · St. Joseph's Healthcare, London, Ontario, Canada · +4 more
A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)
Sunstone Medical
Conditions
Post Traumatic Stress Disorder · PTSD
Phase
Phase 2
Enrollment
70 estimated
Locations
Sunstone Medical, PC, Rockville, Maryland, United States
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder
Johns Hopkins University
Conditions
Tobacco Use Disorder
Phase
Phase 2
Enrollment
66 estimated
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States · Johns Hopkins University School of Medicine, Baltimore, Maryland, United States · New York University, New York, New York, United States
Psilocybin-assisted Existential, Attachment and Relational (PEARL) Therapy for Caregivers of Patients With Advanced Cancer: A Phase II Open-Label Trial
University Health Network, Toronto
Conditions
Caregiver Distress
Phase
Phase 2
Enrollment
15 estimated
Locations
Toronto General Hospital, Toronto, Ontario, Canada
Exploring the Safety, Acceptability, and Efficacy of Psilocybin Among Non-Small Cell Lung Cancer Patients With Major Depressive Disorder: A Proof-of-Concept Trial (DREAM LUNG STUDY)
The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.
University Medical Center Groningen
Conditions
COPD (Chronic Obstructive Pulmonary Disease) · ALS (Amyotrophic Lateral Sclerosis) · MS (Multiple Sclerosis) · Major Depressive Disorder (MDD)
Phase
Phase 2
Enrollment
108 estimated
Locations
National Institute of Mental Health, Prague, Czechia · Bispebjerg Hospital, Copenhagen, Denmark · University Medical Center Groningen, Groningen, Provincie Groningen, Netherlands · +1 more
Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)
University Hospital, Basel, Switzerland
Conditions
Palliative Care · Pain · Anxiety · Depression
Phase
Phase 2
Enrollment
60 estimated
Locations
University Hospital Basel, Division of Clinical Pharmacology and Toxicology, Basel, Switzerland · University Hospital Geneva, Palliative medicine department, Collonge-Bellerive, Switzerland · Spital Uster AG, Division of Internal Medicine, Uster, Switzerland · +1 more
CAPSI - Cancer Related Major Depression Treated With a Single Dose of Psilocybin: A Multicenter Randomized Placebo Controlled Double Blind Clinical Trial
Section for Affective Disorders; Northern Stockholm Psychiatry
Conditions
MDD
Phase
Phase 2
Enrollment
100 estimated
Locations
region Västra Götaland, Gothenburg, Göteborg, Sweden · Norra Stockholms Psykiatri, Stockholm, Stockholm County, Sweden · Psykiatriska Kliniken, Akademiska Sjukhuset, Uppsala, Uppsala County, Sweden · +1 more
Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects: A Randomized, Open-Label, Cross-Over Functional Magnetic Resonance Imaging Trial
Medical University of Vienna
Conditions
Depression - Major Depressive Disorder · Anhedonia
Phase
Phase 1
Enrollment
85 estimated
Locations
Medical University of Vienna, Department of Psychiatry and Psychotherapy, Division of General Psychiatry, Vienna, State of Vienna, Austria
Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study
A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.
Psyence Australia Pty Ltd
Conditions
Adjustment Disorder · Adjustment Disorder With Anxious Mood · Cancer · Cancer Cachexia
Phase
Phase 2
Enrollment
87 estimated
Locations
Mind Medicine Australia Clinic, Abbotsford, Victoria, Australia · Paratus Clinical Research Melbourne, Northcote, Victoria, Australia · Empax Centre, Leederville, Western Australia, Australia
A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone Treatment
NYU Langone Health
Conditions
Opioid Use Disorder
Phase
Phase 2
Enrollment
480 estimated
Locations
Duke City Recovery Toolbox, Albuquerque, New Mexico, United States · University of New Mexico, Albuquerque, New Mexico, United States · StartCare, Brooklyn, New York, United States · +2 more
Investigating the Effects of a Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm Behaviour: an Experimental Medicine Study
Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication in Patients With Chronic Pain: an Open-label Feasibility Study
University of British Columbia
Conditions
Opioid Dependence · Chronic Pain
Phase
Phase 2
Enrollment
10 estimated
Locations
University of British Columbia - Okanagan Campus, Kelowna, British Columbia, Canada
Digital Intervention for Psychedelic Preparation (DIPP): A Randomised Controlled Feasibility Trial Comparing Meditation and Music-Based Programs in Healthy Volunteers.
Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive Disorder
Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC): A Multicenter Triple-blind Phase 2 Randomized Controlled Trial of Psilocybin Therapy for Demoralized Adults Near the End of Life
Charles S. Grob, M.D.
Conditions
Demoralization
Phase
Phase 2
Enrollment
100 estimated
Locations
Marin Cancer Care, Greenbrae, California, United States · University of California, Los Angeles, Los Angeles, California, United States · University of San Francisco, San Francisco, California, United States · +2 more
A Double-blind, Phase II Feasibility Study to Assess the Safety and Efficacy of Psilocybin Microdosing Combined With Psychotherapy in Treatment-resistant Depression
Beersheva Mental Health Center
Conditions
Treatment Resistant Depression
Phase
Phase 2
Enrollment
20 estimated
Locations
Mental Health Center Beer Sheva, Beersheba, Israel
Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients.
Beersheva Mental Health Center
Conditions
Obsessive-compulsive Disorder
Phase
Phase 2
Enrollment
15 estimated
Locations
Beer Sheva Mental Health Center, Beersheba, Israel
Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in a Randomized, Placebo-controlled, Cross-over Trial in Healthy Participants (LPD-Study)
Psilocybin-assisted Psychotherapy in the Treatment of Patients Hospitalized for Treatment-resistant Depression: an Open-label Feasibility Study with an Experiential and Systemic Focus
University Hospital, Ghent
Conditions
Treatment Resistant Depression
Phase
Phase 2
Enrollment
100 estimated
Locations
Ghent University Hospital, Ghent, Oost-Vlaanderen, Belgium
Exact status: this page includes only records whose latest indexed ClinicalTrials.gov overall status is RECRUITING. “Not yet recruiting,” “enrolling by invitation,” and “active, not recruiting” are excluded.
Automatic updates: the list, counts, facets, and map are regenerated from the tracker after scheduled ClinicalTrials.gov refreshes. Registry facts can lag local changes, so the source record remains authoritative.
Rights-safe scope: titles, identifiers, sponsors, design facts, dates, interventions, conditions, and mapped sites are shown. Registry descriptions, contacts, raw payloads, and source-derived keywords are not redistributed.
